CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. COLLABORATION AND...Collaboration and License Agreement • January 28th, 2004 • Abgenix Inc • Biological products, (no disgnostic substances) • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) dated as of October 15, 2003, is entered into by and between, on the one hand, ABGENIX, INC., a Delaware corporation (“ABX”), having a place of business at 6701 Kaiser Drive, Fremont, California 94555, U.S.A., and, on the other hand, ASTRAZENECA UK LTD., a company incorporated in England under no. 3674842 whose registered office is at 15 Stanhope Gate, London, WIK 1LN, England (“AZ”).
SECURITIES PURCHASE AGREEMENT BY AND BETWEEN ABGENIX, INC. AND ASTRAZENECA UK LIMITEDSecurities Purchase Agreement • January 28th, 2004 • Abgenix Inc • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of the 15th day of October, 2003 by and between Abgenix, Inc., a Delaware corporation with its principal office at 6701 Kaiser Drive, Fremont, California 94555, United States of America (the “Company”), and AstraZeneca UK Limited, a company organized under the laws of England with its principal office at Alderley House, Alderley Park, Macclesfield, Cheshire SK10 4TF, United Kingdom (the “Purchaser”).
